PMV in €34.5m Biocartis series-D round

Biocartis will use the funding to commercialise its recently launched DMAT platform, validate its Apollo platform and build up content on both.

Other investors in this round included RMM, Valiance, Debiopharm Group, Korys, Philips, Johnson & Johnson Development Corporation, the family office of Dr Paul Janssen, Luc Verelst, Benaruca and New Rhein Healthcare.

The company previously received €71m in a series-C round in 2011, €30m of funding in 2010 and a €10m Series-A round led by Aescap Venture in 2009, all backed by a core team of existing investors.

Company
Biocartis provides research and diagnostic systems with simultaneous multiplex detection, enabling the firm to provide personalised medicine. Oncology is the primary focus of Biocartis. The company's alliance partners include bioMérieux and Janssen Diagnostics.

Biocartis SA is based at the EPFL's Innovation Square in Lausanne, with a Belgian entity located in Mechelen. The company was founded in 2007 and employs 140 people.

People
Following the fundraising, PMV's Roald Borré will join Biocartis' board.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• DACH
• Healthcare
• Switzerland